Fonte: Clinical lymphoma myeloma & leukemia. Unidade: FM
Assuntos: DOENÇAS HEMATOLÓGICAS, SOBREVIDA, NORTE-AMERICANOS
ABNT
AZEVEDO NETO, Raymundo Soares de et al. Age, Blasts, performance status and lenalidomide therapy influence the outcome of myelodysplastic syndrome with isolated del(5q): a study of 58 South American patients. Clinical lymphoma myeloma & leukemia, v. 22, n. 1, p. E1-E6, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.clml.2021.07.026. Acesso em: 02 nov. 2024.APA
Azevedo Neto, R. S. de, Belli, C., Bassolli, L., Ferri, L., Perusini, M. A., Enrico, A., et al. (2022). Age, Blasts, performance status and lenalidomide therapy influence the outcome of myelodysplastic syndrome with isolated del(5q): a study of 58 South American patients. Clinical lymphoma myeloma & leukemia, 22( 1), E1-E6. doi:10.1016/j.clml.2021.07.026NLM
Azevedo Neto RS de, Belli C, Bassolli L, Ferri L, Perusini MA, Enrico A, Pereira TDM, Junior WFS, Rocha VG, Velloso EDRP. Age, Blasts, performance status and lenalidomide therapy influence the outcome of myelodysplastic syndrome with isolated del(5q): a study of 58 South American patients [Internet]. Clinical lymphoma myeloma & leukemia. 2022 ; 22( 1): E1-E6.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1016/j.clml.2021.07.026Vancouver
Azevedo Neto RS de, Belli C, Bassolli L, Ferri L, Perusini MA, Enrico A, Pereira TDM, Junior WFS, Rocha VG, Velloso EDRP. Age, Blasts, performance status and lenalidomide therapy influence the outcome of myelodysplastic syndrome with isolated del(5q): a study of 58 South American patients [Internet]. Clinical lymphoma myeloma & leukemia. 2022 ; 22( 1): E1-E6.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1016/j.clml.2021.07.026